KOD / Kodiak (KOD) Treats First Patient in Diabetic Macular Edema Study

Kodiak (KOD) reports weaker-than-expected results in second-quarter 2023. The company also provides an update on the status of its pipeline after disc more_horizontal

Kodiak Sciences (KOD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. more_horizontal

Kodiak (KOD) stock plunges as it failed to meet the primary endpoint in phase III studies evaluating tarcocimab in diabetic macular edema patients. more_horizontal

Kodiak Sciences shares fell by more than 45% after the biopharmaceutical company announced that it was discontinuing its tarcocimab program for eye di more_horizontal

Kodiak Sciences Inc decided to discontinue development of its experimental drug to treat a type of eye disorder, sending its shares tumbling 40% in pr more_horizontal

Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? more_horizontal

Kodal Minerals and Hainan Mining have agreed to a long stop extension until 30 June 2023 to ratify the financing package for the Bougouni lithium pro more_horizontal

Kodiak (KOD) focuses on completing ongoing studies on tarcocimab for several retinal indications. However, competition in the market and the lack of o more_horizontal